Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance.

Literature DB >> 19188762

Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance.

André Furco, Bhairvi Gosrani, Sara Nicholas, Amanda Williams, Wunmi Braithwaite, Anton Pozniak, Graham Taylor, David Asboe, Hermione Lyall, Andrew Shaw, Moses Kapembwa.

Abstract

Entities: Chemical Species

Mesh：

Year: 2009 PMID： 19188762 DOI： 10.1097/QAD.0b013e32832027d6

Source DB: PubMed Journal: AIDS ISSN： 0269-9370 Impact factor: 4.177

Keyword Cloud
Cited

× No keyword cloud information.

12 in total

1. Salvage Regimens Containing Darunavir, Etravirine, Raltegravir, or Enfuvirtide in Highly Treatment-Experienced Perinatally Infected Pregnant Women.

Authors: Gail F Shust; Jennifer Jao; Gabriela Rodriguez-Caprio; Roberto Posada; Katherine T Chen; Amelia Averitt; Rhoda S Sperling
Journal: J Pediatric Infect Dis Soc Date: 2013-04-12 Impact factor: 3.164

Review 2. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.

Authors: Martina Penazzato; Carlo Giaquinto
Journal: Drugs Date: 2011-11-12 Impact factor: 9.546

Review 3. Complex decisions in managing HIV infection during pregnancy.

Authors: Mary A Vogler; Harjot Singh; Rodney Wright
Journal: Curr HIV/AIDS Rep Date: 2011-06 Impact factor: 5.071

4. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.

Authors: Alice Stek; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Sandra K Burchett; Regis Kreitchmann; Kittipong Rungruengthanakit; Tim R Cressey; Lynne M Mofenson; Elizabeth Smith; David Shapiro; Mark Mirochnick
Journal: J Acquir Immune Defic Syndr Date: 2015-09-01 Impact factor: 3.731

10. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.

Authors: C D Zorrilla; R Wright; O O Osiyemi; S Yasin; B Baugh; K Brown; B Coate; P Verboven; J Mrus; R Falcon; T N Kakuda
Journal: HIV Med Date: 2013-06-03 Impact factor: 3.180

Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance.

1. Salvage Regimens Containing Darunavir, Etravirine, Raltegravir, or Enfuvirtide in Highly Treatment-Experienced Perinatally Infected Pregnant Women.

Review 2. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.

Review 3. Complex decisions in managing HIV infection during pregnancy.

4. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.

5. Profile of etravirine for the treatment of HIV infection.

Review 6. HIV protease inhibitors in pregnancy : pharmacology and clinical use.

Review 7. Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.

8. Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

Review 9. Pharmacokinetic optimization of antiretroviral therapy in pregnancy.

10. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.